ClinicalTrials.gg
CompletedNCT00475670Updated Sep 15, 2014Results posted

A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer

A Phase 2 interventional study of Trastuzumab and Taxane (docetaxel or paclitaxel) in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 57 sites in 15 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-15.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

How we know · 6 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Enrollment
235th of 366
44 · median 61
Started
2005
with 14 others
Phase 2
239 of 374
44 open now
Registered
95th of 374
by date
Lead sponsor
31 of 374
Hoffmann-La Roche

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 235th largest by enrollment of the 366 interventional ones that give a count, is one of 15 that started in 2005, is one of 239 in phase 2, and was the 95th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This 2 arm study will assess the efficacy and safety of intravenous Herceptin with or without a taxane for the first line treatment of metastatic breast cancer in women who have relapsed at least 12 months after a minimum of 10 months of (neo)adjuvant treatment with Herceptin for HER2-positive early breast cancer.Patients will receive either Herceptin monotherapy (loading dose of 4mg/kg iv, followed by weekly doses of 2mg/kg iv, or 8mg/kg loading dose followed by 3-weekly doses of 6mg/kg)or Herceptin + a taxane (docetaxel 100mg/m2 iv every 3 weeks, or paclitaxel 175mg/m2 iv every 3 weeks or 75mg/m2 every week). The anticipated time on study treatment is until disease progression, and the target sample size is \<100 individuals.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • at least 10 months of Herceptin treatment for -positive early breast cancer;
  • breast cancer >=12 months after discontinuation of Herceptin;
  • .

Exclusion criteria

Exclusion Criteria:

  • previous chemotherapy for breast cancer;
  • ;
  • invasive other than metastatic breast cancer.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Active comparator
    Trastuzumab Monotherapy

    Participants received an initial loading dose of 4 milligrams per kilogram (mg/kg) trastuzumab intravenous (i.v.) on Day 1, followed by 2mg/kg i.v. weekly, or an initial loading dose of 8 mg/kg i.v. loading dose on Day 1, followed by 6 mg/kg i.v. every 3 weeks, until disease progression, unacceptable toxicity, withdrawal or death.

    Drug: Trastuzumab

  • Experimental
    Trastuzumab, Taxane

    Participant received an initial loading dose of 4 mg/kg trastuzumab i.v. on Day 1, followed by 2mg/kg i.v. weekly, or an initial loading dose of 8 mg/kg i.v. loading dose, followed by 6 mg/kg i.v. every 3 weeks, until disease progression, unacceptable toxicity, withdrawal or death; and concomitant taxane, which is either 100 milligrams per square meter (mg/m2) docetaxel i.v. every 3 weeks, or 75 mg/m2 weekly or 175 mg/m2 every 3 weeks paclitaxel for at least 18 weeks, or more at the discretion of the investigator.

    Drug: Trastuzumab · Drug: Taxane (docetaxel or paclitaxel)

Interventions

  • 4 mg/kg i.v. loading dose on Day 1, followed by 2 mg/kg i.v. weekly; or 8 mg/kg i.v. loading dose, followed by 6 mg/kg i.v. every 3 weeks until disease progression, unacceptable toxicity, withdrawal or death.

    Also known as: Herceptin

  • DrugTaxaneStudies of TaxaneTaxane pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Docetaxel 100 mg/m2 i.v. every 3 weeks, or paclitaxel administered in a dose of 75 mg/m2 i.v. weekly or 175 mg/m2 i.v. every 3 weeks for at least 18 weeks, or more at the discretion of the investigator. Choice of taxane at the discretion of the investigator. Taxane may be administered at the same time, or 24 hours after, administration of trastuzumab.

    Also known as: Docetaxel, Paclitaxel

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) According to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 Guidelines

    CR was defined for target lesions (TLs) as the disappearance of all lesions, and for nontarget lesions (NTLs) as the disappearance of all nontarget nonmeasurable lesions. PR was defined for TLs as at least a 30 percent (%) decrease from baseline (BL) in the sum of longest diameter (SLD) of TLs. 95% confidence interval for one-sample binomial using Pearson-Clopper method.

    Time frame: Baseline (BL); Day 1 of Weeks 7, 13, 19, 25, 37, and 52, at the last administration of study treatment, every 24 weeks thereafter until disease progression for up to 6 months after the last participant was recruited

Secondary outcomes

  1. Duration of Response - Percentage of Participants With Progressive Disease or Death

    Duration of response was defined as the time from first confirmed CR or PR until death or progressive disease (PD). For TLs, PD was defined as at least a 20% increase in the SLD of the TL, taking as reference the smallest SLD recorded since the beginning of treatment or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of one or more new lesions or unequivocal progression of existing non target non-measurable lesions. Participants were censored at the date of the last tumor assessment.

    Time frame: BL, Day 1 of Weeks 7, 13, 19, 25, 37, and 52, at the last administration of study treatment, every 24 weeks thereafter until disease progression for up to 6 months after the last participant was recruited

  2. Duration of Response

    The time, in months, from when the response (CR or PR) was first noted until the date of documented PD, death, or withdrawal, whichever occurred first. Participants were censored at the date of the last tumor assessment.

    Time frame: BL, Day 1 of Weeks 7, 13, 19, 25, 37, and 52, at the last administration of study treatment, every 24 weeks thereafter until disease progression for up to 6 months after the last participant was recruited

  3. Progression-free Survival (PFS) - Percentage of Participants With Progressive Disease

    PFS was defined as the time from day of first study drug infusion until death or PD. Participants were censored at the date of the last tumor assessment.

    Time frame: BL, Day 1 of Weeks 7, 13, 19, 25, 37, and 52, at the last administration of study treatment, every 24 weeks thereafter until disease progression for up to 6 months after the last participant was recruited

  4. Progression-Free Survival

    The time, in months, from BL to PFS event.

    Time frame: BL, Day 1 of Weeks 7, 13, 19, 25, 37, and 52, at the last administration of study treatment, every 24 weeks thereafter until disease progression for up to 6 months after the last participant was recruited

  5. Percentage of Participants With Treatment Failure

    Treatment failure was defined as the time from first study drug infusion to failure. Failure was defined as any of the following: PD, death, withdrawal due to adverse event (AE) or lab abnormality, or refusal of treatment. Participants were censored at the last date recorded in the case report form (CRF) or the date of withdrawal.

    Time frame: BL, Day 1 of Weeks 7, 13, 19, 25, 37, and 52, at the last administration of study treatment, every 24 weeks thereafter until disease progression for up to 6 months after the last participant was recruited

  6. Time to Treatment Failure

    The time, in months, from BL to treatment failure.

    Time frame: BL, Day 1 of Weeks 7, 13, 19, 25, 37, and 52, at the last administration of study treatment, every 24 weeks thereafter until disease progression for up to 6 months after the last participant was recruited

  7. Percentage of Participants With Clinical Benefit According to RECIST Guidelines

    Clinical benefit was defined as stable disease (SD) for 6 months or longer, or a confirmed overall response of CR or PR. For TLs, SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD since the beginning of treatment. For NTLs, SD was synonymous with incomplete response and defined as the persistence of one or more NTLs and/or maintenance of tumor marker level above the normal limits.

    Time frame: BL, Day 1 of Weeks 7, 13, 19, 25, 37, and 52, at the last administration of study treatment, every 24 weeks thereafter until disease progression for up to 6 months after the last participant was recruited

  8. Overall Survival - Percentage of Participants Who Died

    OS was defined as the time from the date of enrollment to the date of death due to any cause. Participants were censored at the last date recorded in the CRF.

    Time frame: BL, Day 1 of Weeks 1, 4, 7, 10, 13, 16, 19, 25, 37, and 5 at the last administration of study treatment, every 24 weeks thereafter until disease progression or death, yearly thereafter up to 2 years after cessation of recruitment

  9. Overall Survival

    The time, in months, from BL to death due to any cause.

    Time frame: BL, Day 1 of Weeks 1, 4, 7, 10, 13, 16, 19, 25, 37, and 52 at the last administration of study treatment, every 24 weeks thereafter until disease progression or death, yearly thereafter up to 2 years after cessation of recruitment

07

Results

Posted Sep 15, 2014
Limitations and caveats
Cohort A (trastuzumab monotherapy) was closed prematurely due to enrollment difficulties. Therefore, Cohort A included only 3 participants.

Participant flow

Participant flow — Overall Study
MilestoneTrastuzumab MonotherapyTrastuzumab, Taxane
Started341
Completed00
Not completed341
Withdrew: Death01
Withdrew: Lack of efficacy334
Withdrew: Refused treatment02
Withdrew: Failure to return01
Withdrew: Other03

Outcome measures

PrimaryPercentage of Participants Achieving Complete Response (CR) or Partial Response (PR) According to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 Guidelines

CR was defined for target lesions (TLs) as the disappearance of all lesions, and for nontarget lesions (NTLs) as the disappearance of all nontarget nonmeasurable lesions. PR was defined for TLs as at least a 30 percent (%) decrease from baseline (BL) in the sum of longest diameter (SLD) of TLs. 95% confidence interval for one-sample binomial using Pearson-Clopper method.

Time frame:
Baseline (BL); Day 1 of Weeks 7, 13, 19, 25, 37, and 52, at the last administration of study treatment, every 24 weeks thereafter until disease progression for up to 6 months after the last participant was recruited
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) According to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 Guidelines
percentage of participantsTrastuzumab MonotherapyTrastuzumab, Taxane
Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) According to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 Guidelines—61.0 (48.7 to 80.4)
SecondaryDuration of Response - Percentage of Participants With Progressive Disease or Death

Duration of response was defined as the time from first confirmed CR or PR until death or progressive disease (PD). For TLs, PD was defined as at least a 20% increase in the SLD of the TL, taking as reference the smallest SLD recorded since the beginning of treatment or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of one or more new lesions or unequivocal progression of existing non target non-measurable lesions. Participants were censored at the date of the last tumor assessment.

Time frame:
BL, Day 1 of Weeks 7, 13, 19, 25, 37, and 52, at the last administration of study treatment, every 24 weeks thereafter until disease progression for up to 6 months after the last participant was recruited
Reported as:
Number · percentage of participants
Duration of Response - Percentage of Participants With Progressive Disease or Death
percentage of participantsTrastuzumab MonotherapyTrastuzumab, Taxane
Duration of Response - Percentage of Participants With Progressive Disease or Death—88.0
SecondaryDuration of Response

The time, in months, from when the response (CR or PR) was first noted until the date of documented PD, death, or withdrawal, whichever occurred first. Participants were censored at the date of the last tumor assessment.

Time frame:
BL, Day 1 of Weeks 7, 13, 19, 25, 37, and 52, at the last administration of study treatment, every 24 weeks thereafter until disease progression for up to 6 months after the last participant was recruited
Reported as:
Median · months
Duration of Response
monthsTrastuzumab MonotherapyTrastuzumab, Taxane
Duration of Response—8.0 (5 to 15)
SecondaryProgression-free Survival (PFS) - Percentage of Participants With Progressive Disease

PFS was defined as the time from day of first study drug infusion until death or PD. Participants were censored at the date of the last tumor assessment.

Time frame:
BL, Day 1 of Weeks 7, 13, 19, 25, 37, and 52, at the last administration of study treatment, every 24 weeks thereafter until disease progression for up to 6 months after the last participant was recruited
Reported as:
Number · percentage of participants
Progression-free Survival (PFS) - Percentage of Participants With Progressive Disease
percentage of participantsTrastuzumab MonotherapyTrastuzumab, Taxane
Progression-free Survival (PFS) - Percentage of Participants With Progressive Disease—87.8
SecondaryProgression-Free Survival

The time, in months, from BL to PFS event.

Time frame:
BL, Day 1 of Weeks 7, 13, 19, 25, 37, and 52, at the last administration of study treatment, every 24 weeks thereafter until disease progression for up to 6 months after the last participant was recruited
Reported as:
Median · months
Progression-Free Survival
monthsTrastuzumab MonotherapyTrastuzumab, Taxane
Progression-Free Survival—8.0 (6 to 11)
SecondaryPercentage of Participants With Treatment Failure

Treatment failure was defined as the time from first study drug infusion to failure. Failure was defined as any of the following: PD, death, withdrawal due to adverse event (AE) or lab abnormality, or refusal of treatment. Participants were censored at the last date recorded in the case report form (CRF) or the date of withdrawal.

Time frame:
BL, Day 1 of Weeks 7, 13, 19, 25, 37, and 52, at the last administration of study treatment, every 24 weeks thereafter until disease progression for up to 6 months after the last participant was recruited
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Failure
percentage of participantsTrastuzumab MonotherapyTrastuzumab, Taxane
Percentage of Participants With Treatment Failure—95.1
SecondaryTime to Treatment Failure

The time, in months, from BL to treatment failure.

Time frame:
BL, Day 1 of Weeks 7, 13, 19, 25, 37, and 52, at the last administration of study treatment, every 24 weeks thereafter until disease progression for up to 6 months after the last participant was recruited
Reported as:
Median · months
Time to Treatment Failure
monthsTrastuzumab MonotherapyTrastuzumab, Taxane
Time to Treatment Failure—8.0 (6 to 11)
SecondaryPercentage of Participants With Clinical Benefit According to RECIST Guidelines

Clinical benefit was defined as stable disease (SD) for 6 months or longer, or a confirmed overall response of CR or PR. For TLs, SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD since the beginning of treatment. For NTLs, SD was synonymous with incomplete response and defined as the persistence of one or more NTLs and/or maintenance of tumor marker level above the normal limits.

Time frame:
BL, Day 1 of Weeks 7, 13, 19, 25, 37, and 52, at the last administration of study treatment, every 24 weeks thereafter until disease progression for up to 6 months after the last participant was recruited
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Benefit According to RECIST Guidelines
percentage of participantsTrastuzumab MonotherapyTrastuzumab, Taxane
Percentage of Participants With Clinical Benefit According to RECIST Guidelines—70.7 (54.5 to 83.9)
SecondaryOverall Survival - Percentage of Participants Who Died

OS was defined as the time from the date of enrollment to the date of death due to any cause. Participants were censored at the last date recorded in the CRF.

Time frame:
BL, Day 1 of Weeks 1, 4, 7, 10, 13, 16, 19, 25, 37, and 5 at the last administration of study treatment, every 24 weeks thereafter until disease progression or death, yearly thereafter up to 2 years after cessation of recruitment
Reported as:
Number · percentage of participants
Overall Survival - Percentage of Participants Who Died
percentage of participantsTrastuzumab MonotherapyTrastuzumab, Taxane
Overall Survival - Percentage of Participants Who Died—63.4
SecondaryOverall Survival

The time, in months, from BL to death due to any cause.

Time frame:
BL, Day 1 of Weeks 1, 4, 7, 10, 13, 16, 19, 25, 37, and 52 at the last administration of study treatment, every 24 weeks thereafter until disease progression or death, yearly thereafter up to 2 years after cessation of recruitment
Reported as:
Median · months
Overall Survival
monthsTrastuzumab MonotherapyTrastuzumab, Taxane
Overall Survival—25.0 (16 to 33)

Adverse events

Collected over Adverse events and serious adverse events were recorded from study start to 28 days after the last dose of study drug. Serious adverse events that were related to study medication or were cardiac are reported until 2 years after enrollment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab Monotherapy—0/3 (0%)3/3 (100%)
Trastuzumab, Taxane—6/41 (14.6%)36/41 (87.8%)
Most frequent serious events
Most frequent serious events
EventTrastuzumab MonotherapyTrastuzumab, Taxane
Bacterial InfectionInfections and infestations0/31/41
BronchitisInfections and infestations0/31/41
SepsisInfections and infestations0/31/41
Febrile NeutropeniaBlood and lymphatic system disorders0/31/41
NeutropeniaBlood and lymphatic system disorders0/31/41
Sudden DeathGeneral disorders0/31/41
LymphoedemaVascular disorders0/31/41
Most frequent other events
Showing 10 of 29
Most frequent other events
EventTrastuzumab MonotherapyTrastuzumab, Taxane
Oedema peripheralGeneral disorders1/37/41
PyrexiaGeneral disorders1/36/41
Back painMusculoskeletal and connective tissue disorders1/34/41
Musculoskeletal painMusculoskeletal and connective tissue disorders1/33/41
HeadacheNervous system disorders1/33/41
DyspnoeaRespiratory, thoracic and mediastinal disorders1/34/41
Urinary tract infectionInfections and infestations1/30/41
CoughRespiratory, thoracic and mediastinal disorders1/30/41
DiarrhoeaGastrointestinal disorders0/313/41
AlopeciaSkin and subcutaneous tissue disorders0/313/41

Baseline characteristics

Full analysis set (FAS) included all enrolled participants who received at least one dose of either trastuzumab or taxane.

Age, Continuous
Age, Continuous(years)Trastuzumab MonotherapyTrastuzumab, TaxaneTotal
Median40 (35 to 58)54 (31 to 78)54 (31 to 78)
Sex: Female, Male
Sex: Female, Male(Participants)Trastuzumab MonotherapyTrastuzumab, TaxaneTotal
Female34144
Male000
08

Study locations

57 sites
  • Geelong, Victoria 3220, Australia
  • Klagenfurt, 9026, Austria
  • Salzburg, 5020, Austria
  • Vöcklabruck, 4840, Austria
  • Wien, 1090, Austria
  • Brussel, 1090, Belgium
  • Namur, 5000, Belgium
  • Porto Alegre, RS 90610-000, Brazil
  • Porto Alegre, RS 91350-200, Brazil
  • Winnipeg, Manitoba R2H 2A6, Canada
  • Brampton, Ontario L6R 3J7, Canada
  • Oshawa, Ontario L1G 2B9, Canada
  • Greenfield Park, Quebec J4V 2H1, Canada
  • Beijing, 100021, China
  • Guangzhou, 510060, China
  • Shanghai, 200032, China
  • Wuhan, 430030, China
  • Berlin, 12203, Germany
  • Düsseldorf, 40225, Germany
  • Hamburg, 20246, Germany
  • Krefeld, 47805, Germany
  • Köln, 50931, Germany
  • Lemgo, 32657, Germany
  • München, 81675, Germany
  • Tübingen, 72076, Germany
  • Budapest, 1031, Hungary
  • Budapest, 1083, Hungary
  • Budapest, 1122, Hungary
  • Budapest, 1145, Hungary
  • Kecskemet, 6000, Hungary
  • Szeged, 6701, Hungary
  • Chieti, 66100, Italy
  • Genova, 16132, Italy
  • Roma, 00168, Italy
  • San Giovanni Rotondo, 71013, Italy
  • Sassari, 07100, Italy
  • Merida, 97500, Mexico
  • Panama City, 83-0669, Panama
  • Gdansk, 80-214, Poland
  • Gliwice, 44-101, Poland
  • Lodz, 94-306, Poland
  • Kazan, 420029, Russian Federation
  • Moscow, 115478, Russian Federation
  • Saint-Petersburg, 197758, Russian Federation
  • La Coruna, La Coruña 15009, Spain
  • Barcelona, 08035, Spain
  • Barcelona, 08036, Spain
  • Jaen, 23007, Spain
  • Madrid, 28041, Spain
  • Valencia, 46009, Spain
  • Valencia, 46010, Spain
  • Zaragoza, 50009, Spain
  • Changhua, 500, Taiwan
  • Taipei, 00112, Taiwan
  • Taipei, 100, Taiwan
  • Taipei, Taiwan
  • Taoyuan, 333, Taiwan
09

References and documents

Publications

  • Lang I, Bell R, Feng FY, Lopez RI, Jassem J, Semiglazov V, Al-Sakaff N, Heinzmann D, Chang J. Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial. Clin Oncol (R Coll Radiol). 2014 Feb;26(2):81-9. doi: 10.1016/j.clon.2013.08.011. Epub 2013 Sep 17. PubMed 24051172 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2007
First posted
May 21, 2007
Start
Oct 2005
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Results first posted
Sep 15, 2014
Last update
Sep 15, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00475670
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 21, 2007
Start date
Oct 2005
Primary completion
Jun 2012
Completion
Jun 2012
Results posted
Sep 15, 2014
Last update
Sep 15, 2014

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trastuzumab · Taxane

Start the discussion